LUND, Sweden ― Immunovia AB today introduces its website in Swedish as part of the efforts to grow its presence in the Scandinavian home markets. The company launched its global website one year ago and online reports show high total number of visitors from all around the world. However, since December last year, when the company was listed on Nasdaq First North in Stockholm, a lot of additional traffic to the website comes from the Swedish audience.
“As we start to grow globally and expand into strategic markets, enabling local customers and investors to explore and learn about our solutions and news in Swedish is very important to our success. This new site is another step in our continuous mission to answer to the needs of all our stakeholders from the investors, to the clinicians, to the payers and to the patients,” said Mats Grahn, CEO, Immunovia.
For more information, please contact: Mats Grahn Chief Executive Officer, CEO, ImmunoviaTel.: +46-70-5320230
Email: mats.grahn@immunovia.com
Read more about Immunovia and IMMray™ technology: www.immunovia.com
We look forward to receiving your feedback at info@immunovia.com.
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
###
